Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

But will the FDA accept the surrogate endpoint used in ASC4First?

This weekend’s oncology conference will feature at least 30 different ADC projects.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.